MAP2K7 and neoplasm: The combination of agonist antibodies (ABS) targeting the immunostimulatory CD40 receptor plus MEK inhibitors suppressing M2 macrophages, bone marrow-derived suppressor cells, and T regulatory cells generates a potent synergistic anti-tumor effect [69].